Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
February 2, 2004
- BUSINESS NEWS IN BRIEF
February 2, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 2, 2004
- Annual Business Results
February 2, 2004
- WORLD NEWS IN BRIEF
February 2, 2004
- NHI Price Reductions by Re-pricing Rule Unlikely This Year
February 2, 2004
- Roche Diagnostics Aims to Reach Sales of \60 Bil. in 2008: Mr Ogawa
February 2, 2004
- Newly Launched Generics to Be Applied to 70%- Multiple Rule
February 2, 2004
- Antihistamic Drugs Making Stiffer Competition
February 2, 2004
- REGULATORY NEWS IN BRIEF
February 2, 2004
- Meiji Seika Kaisha Aiming for Record Profits in FY2005
February 2, 2004
- Market-based Healthcare Reform Criticized: Seminar
February 2, 2004
- Korosho Proposes DPC Review Policy
February 2, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 2, 2004
- LTT Bio-Pharma Starts PI Trial on PC-SOD
February 2, 2004
- Generic Drugs Had 13.1% Share of Ethical Sales Volume in FY2002: EPMA
January 26, 2004
- DIAGNOSTIC NEWS IN BRIEF
January 26, 2004
- Kirin's Pharma Division Aims for Sales of \70 Bil. in 2006
January 26, 2004
- Meet the Leaders (30)
January 26, 2004
- Toho to Enhance Solution Proposals to Customers
January 26, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…